Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges

In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Pardo, Miguel, Makarem, Maisam, Li, Janice J. N., Kelly, Deirdre, Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381753/
https://www.ncbi.nlm.nih.gov/pubmed/35347327
http://dx.doi.org/10.1038/s41416-022-01776-9
_version_ 1784769144055398400
author García-Pardo, Miguel
Makarem, Maisam
Li, Janice J. N.
Kelly, Deirdre
Leighl, Natasha B.
author_facet García-Pardo, Miguel
Makarem, Maisam
Li, Janice J. N.
Kelly, Deirdre
Leighl, Natasha B.
author_sort García-Pardo, Miguel
collection PubMed
description In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical practice for molecular profiling. ctDNA has also emerged as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. In this Review, we discuss current and future clinical applications of ctDNA primarily in non-small cell lung cancer in addition to other solid tumours.
format Online
Article
Text
id pubmed-9381753
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93817532022-08-18 Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges García-Pardo, Miguel Makarem, Maisam Li, Janice J. N. Kelly, Deirdre Leighl, Natasha B. Br J Cancer Review Article In the current era of precision medicine, the identification of genomic alterations has revolutionised the management of patients with solid tumours. Recent advances in the detection and characterisation of circulating tumour DNA (ctDNA) have enabled the integration of liquid biopsy into clinical practice for molecular profiling. ctDNA has also emerged as a promising biomarker for prognostication, monitoring disease response, detection of minimal residual disease and early diagnosis. In this Review, we discuss current and future clinical applications of ctDNA primarily in non-small cell lung cancer in addition to other solid tumours. Nature Publishing Group UK 2022-03-26 2022-09-01 /pmc/articles/PMC9381753/ /pubmed/35347327 http://dx.doi.org/10.1038/s41416-022-01776-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
García-Pardo, Miguel
Makarem, Maisam
Li, Janice J. N.
Kelly, Deirdre
Leighl, Natasha B.
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title_full Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title_fullStr Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title_full_unstemmed Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title_short Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
title_sort integrating circulating-free dna (cfdna) analysis into clinical practice: opportunities and challenges
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381753/
https://www.ncbi.nlm.nih.gov/pubmed/35347327
http://dx.doi.org/10.1038/s41416-022-01776-9
work_keys_str_mv AT garciapardomiguel integratingcirculatingfreednacfdnaanalysisintoclinicalpracticeopportunitiesandchallenges
AT makaremmaisam integratingcirculatingfreednacfdnaanalysisintoclinicalpracticeopportunitiesandchallenges
AT lijanicejn integratingcirculatingfreednacfdnaanalysisintoclinicalpracticeopportunitiesandchallenges
AT kellydeirdre integratingcirculatingfreednacfdnaanalysisintoclinicalpracticeopportunitiesandchallenges
AT leighlnatashab integratingcirculatingfreednacfdnaanalysisintoclinicalpracticeopportunitiesandchallenges

Ejemplares similares